General MedicationsORALStandard

STRIBILD

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Standard Dose

150MG;150MG;200MG;300MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview STRIBILD is listed in Drugs@FDA under application 203100 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET;ORAL - 150MG;150MG;200MG;300MG Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2021-09-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview STRIBILD is listed in Drugs@FDA under application 203100 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE Form and strength TABLET;ORAL - 150MG;150MG;200MG;300MG Sponsor GILEAD SCIENCES INC Submission history Latest submission status date: 2021-09-09 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.